Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Bendazac (Bendazolic acid) is an anticataract drug. It may act by preventing protein denaturation.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
100 mg | In stock | $ 41.00 |
Description | Bendazac (Bendazolic acid) is an anticataract drug. It may act by preventing protein denaturation. |
In vitro | Bendazac (bendazac L-lysine and sodium) inhibits the early stages of protein glycation, as well as the formation of fluorescent advanced glycation products.?Bendazac lysine (20 mM) proved to be more effective in inhibiting fluorescence development (67% inhibition) that the corresponding sodium salt (35% inhibition).?No significant differences were found with respect to furosine levels ;?about 40% inhibition was produced with either bendazac lysine or sodium salt bendazac clearly inhibits glycation of human lens crystallins, as can be efficiently monitored by following specific changes in lens protein fluorescence[1] |
Synonyms | AF-983, Bendazolic acid |
Molecular Weight | 282.29 |
Formula | C16H14N2O3 |
CAS No. | 20187-55-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 60 mg/mL (212.55 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Bendazac 20187-55-7 Others cataractogenic antinecrotic inhibit choleretic protein inflammatory antilipidaemic denaturation AF 983 AF-983 Inhibitor Bendazolic acid AF983 inhibitor